Publications by authors named "Brian Topp"

Claim this Profile
E
Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti-PD-1-refractory Hodgkin lymphoma.
Philippe Armand, Pier Luigi Zinzani, John Timmerman, Nathalie A Johnson, David Lavie, Brian G Topp

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A bootstrapping method to optimize go/no-go decisions from single-arm, signal-finding studies in oncology.
Raunak Dutta, Aparna Mohan, Jacqueline Buros-Novik, Gregory Goldmacher, Omobolaji O Akala, Brian Topp

CPT Pharmacometrics Syst Pharmacol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee.
Anne Monette, Sarah Warren, J Carl Barrett, Charlie Garnett-Benson, Kurt A Schalper, Brian Topp

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
Brian G Topp, Madhav Channavazzala, Kapil Mayawala, Dinesh P De Alwis, Eric Rubin

Cancer Cell· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RECISTv1.1 progression in oncology: Shades of gray.
Brian Topp, Alexandra Snyder, Jedd Wolchok

Cancer Cell· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating lesion-to-lesion heterogeneity into early oncology decision making.
Rukmini Kumar, Timothy Qi, Yanguang Cao, Brian Topp

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors.
Aymara Sancho-Araiz, Sara Zalba, María J Garrido, Pedro Berraondo, Brian Topp

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response.
Rukmini Kumar, Kannan Thiagarajan, Lakshmanan Jagannathan, Liming Liu, Kapil Mayawala, Brian Topp

CPT Pharmacometrics Syst Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1.
Sara Zalba, Virginia Belsúe, Brian Topp, Dinesh de Alwis, Maite Alvarez

Br J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities.
Erica L Bradshaw, Mary E Spilker, Richard Zang, Loveleena Bansal, Handan He, Brian Topp

CPT Pharmacometrics Syst Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industrialization of Quantitative Systems Pharmacology.
Brian Topp, Maria E Trujillo, Vikram Sinha

CPT Pharmacometrics Syst Pharmacol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.
Marjoleen J M A Nijsen, Fan Wu, Loveleena Bansal, Erica Bradshaw-Pierce, Jason R Chan, Brian Topp

CPT Pharmacometrics Syst Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of the relationship between glycemia and beta-cell mass adaptation in vivo.
Laura L Atkinson, Brian G Topp, Jenny Au, Horatiu V Vinerian, Narinder Dhatt

Can J Physiol Pharmacol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.
Steven B Waters, Brian G Topp, Scott Q Siler, Charles M Alexander

J Diabetes Sci Technol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of insulin sensitivity, -cell function, and -cell mass during the development of diabetes in fa/fa rats.
Brian G Topp, Laura L Atkinson, Diane T Finegood

Am J Physiol Endocrinol Metab· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
beta-cell deterioration - prospects for reversal or prevention.
Diane T. Finegood, Brian G. Topp

Diabetes Obes Metab· August 2001

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis